Niacinamide ascorbate
Niacinamide ascorbate is a micronutrient with radioprotective properties. Niacinamide ascorbate works as an antioxidant along with vitamin C, vitamin E and other compounds to mitigate the risks associated with exposure to ionizing radiation. Niacinamide ascorbate helps reduce the likelihood of radiation-induced diseases such as acute leukemia, breast cancer, thyroid cancer and mutations, thereby protecting the human body from the harmful effects of radiation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1987-71-9
- Formule: C12H14N2O7
- Masse moléculaire:298.25
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Chemical Information
-
CAS No. 1987-71-9
-
Masse moléculaire 298.25
-
Formule C12H14N2O7
-
SMILES
OC([C@@]1([H])[C@H](CO)O)=C(O)C(O1)=O.O=C(N)C2=CC=CN=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)